DISCOVER TYVASO DPI

Skip to main content
SELECT A CONDITION

TYVASO and TYVASO DPI are approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

SELECT A CONDITION
hand holding TYVASO DPI inhaler

TYVASO DPI FITS IN THE PALM OF YOUR HAND

hand holding TYVASO DPI inhaler mobile version

Ask your healthcare provider about the Dry Powder Inhaler (DPI) option now approved for TYVASO.

bubbles version 1 bubbles version 2
pocket

CONVENIENTLY
PORTABLE

finger snap

SINGLE-DOSE
CARTRIDGES PREFILLED
WITH MEDICINE

holding up one finger

JUST 1 BREATH
PER CARTRIDGE,
4X DAILY

Taking a dose is as simple as:
JUST ONE BREATH—
OPEN, LOAD, INHALE

Watch this video to see how
simple it is to use TYVASO DPI.

thumbs up

98% Patient Satisfaction with TYVASO DPI

TYVASO DPI received high satisfaction marks from 45 of 46 people in a clinical study who switched from the TYVASO nebulizer.*

DOSING WITH TYVASO DPI

The simple-to-use TYVASO DPI
fits in the palm of your hand.

Doses are taken in 1 breath per cartridge, 4x daily.
Most patients use just 1 cartridge.

  • Available in a variety of cartridge strengths, which
    are color-coded to help you know which ones to take
  • Each dose is inhaled in less than 2 seconds
bubbles version 4 TYVASO DPI inhaler and cartridges

Your medicine will be shipped directly to you in a kit that
contains all that you need to start and continue with TYVASO DPI. bubbles version 5

bubbles version 6
calendar

Each kit is conveniently packed with a 4-week supply
of disposable inhalers and cartridges.

*In the clinical study, 51 people with PAH who had been using the TYVASO nebulizer for at least 3 months switched to TYVASO DPI. Researchers recorded side effects, and after 3 weeks, 46 patients rated their satisfaction with TYVASO DPI in a questionnaire.

Learn more about TYVASO for

PAH (WHO Group 1)
Pulmonary arterial hypertension

PH-ILD (WHO Group 3)
Pulmonary hypertension associated
with interstitial lung disease

arrow to pulmonary arterial hypertension with interstital lung disease

IMPORTANT SAFETY
INFORMATION

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
EXPAND

IMPORTANT SAFETY
INFORMATION

COLLAPSE

Before you take TYVASO or TYVASO DPI, tell your healthcare provider about all of your medical conditions, including if you:

  • Have low blood pressure
  • Have or have had bleeding problems
  • Have asthma or chronic obstructive pulmonary disease (COPD)
  • Are pregnant or plan to become pregnant. It is not known if either product will harm your unborn baby.
  • Are breastfeeding or plan to breastfeed. It is not known if either product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Either product and other medicines may affect each other.

Especially tell your healthcare provider if you take:

  • Medicines used to treat high blood pressure or heart disease
  • Medicines that decrease blood clotting (anticoagulants)
  • Water pills (diuretics)
  • Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®)

What are the possible side effects of TYVASO or TYVASO DPI?

Both products can cause serious side effects, including:

  • Low blood pressure (symptomatic hypotension). If you have low blood pressure, either product may lower your blood pressure more.
  • Bleeding problems. Either product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants).

The most common side effects of both products are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking TYVASO or TYVASO DPI because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing.

You may report side effects to the FDA at 

You are now leaving the Tyvaso.com website

This link will take you to a site maintained by a third party who is solely responsible for the site’s content. Click CONTINUE to proceed or CLOSE to return to www.TYVASO.com.

CONTINUE
www.fda.gov/MedWatch

or call 1-800-FDA-1088.

What are TYVASO and TYVASO DPI?

TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are prescription medicines used in adults to treat:

  • Pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. TYVASO or TYVASO DPI can improve the ability to exercise. Your ability to exercise decreases 4 hours after taking TYVASO or TYVASO DPI. It is not known if TYVASO or TYVASO DPI is safe and effective in children under 18 years of age.
  • Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3), which is high blood pressure in the lungs due to inflammation and sometimes scarring in the lungs. TYVASO or TYVASO DPI can improve the ability to exercise.

The risk information provided here is not comprehensive. To learn more about TYVASO or TYVASO DPI, talk with your healthcare provider. Please see Full Prescribing Information for TYVASO or TYVASO DPI, Instructions for Use manuals for TD-100 and TD-300 TYVASO® Inhalation System and TYVASO DPI® Inhalation Powder, and additional information at www.TYVASO.com or call 1-844-UNITHER (1-844-864-8437).


TYVISIconSEP2024

WHO=World Health Organization.

Privacy Policy Consumer Health Privacy Terms of Use
Privacy Policy Consumer Health Privacy Terms of Use

This site is intended for use by US residents only.

TYVASO and TYVASO DPI are registered trademarks of United Therapeutics Corporation.

© 2024 United Therapeutics Corporation. All rights reserved. US/TYV/0576